



WORLD CANCER DAY: TOGETHER WE CAN BEAT CANCER

To mark World Cancer Day, the Movember Foundation is today encouraging collaboration in cancer research to enable groundbreaking discoveries and help millions of men living with cancer worldwide.

As the largest non-government investor in prostate cancer research globally the Foundation also announced it is investing \$9 million to fund the world's first randomised controlled clinical trial to examine the effect of exercise on overall survival and quality of life for men with prostate cancer.

The trial, part of the Foundation's Global Action Plan (GAP), will investigate the potential of exercise to improve overall survival, quality of life and symptom severity in men with advanced prostate cancer. The project highlights the Movember Foundation's commitment to facilitating collaboration in research to avoid duplication and accelerate outcomes for men around the world.

Around 900 patients will take part, conducted at 20 sites in seven countries around the world as part of the Movember Foundation's commitment to improved health outcomes for men with prostate cancer.

Prostate cancer is the most commonly diagnosed cancer in Australian men and more men will die of the disease than women die of breast cancer.

While previous research has demonstrated that men engaging in vigorous exercise at diagnosis may significantly reduce their risk of progressing to fatal prostate cancer, there is currently a lack of research exploring the benefits of exercise for men with the advanced form of the disease.

This trial will bring together exercise physiologists and uro-oncologists, two professions who rarely have the opportunity to work together but whose shared insights may lead to men using exercise as a treatment for their prostate cancer in the near future.

Paul Villanti, Executive Director of Programs for the Movember Foundation, said the Foundation's innovative funding model encourages researchers to share results, learnings, successes and failures and avoid the duplication of work.

"Funding projects such as this trial as part of our Global Action Plan will lead to an acceleration of results that will positively impact and benefit men diagnosed and living with cancer," said Mr Villanti.

"In the world of cancer research, collaboration is a different approach – personal interests such as profit, competition, rivalry or recognition need to be put aside. The Movember Foundation is uniquely placed to mobilise clinical and scientific leaders from around the world to explore this vital avenue of research and strive to break new ground in the global fight against prostate cancer," he added.

This trial, amongst others that the Movember Foundation is funding around the world, has the potential to change the way men are treated for cancer, ultimately leading to better



outcomes after their diagnosis and more men around the world living happier, healthier and longer lives.

NOTES TO EDITORS

- Local case studies are available for interview on request
- For more information and to arrange an interview with a Movember Foundation spokesperson, contact:
Molly Hyndman (0418 536 528 or molly.hyndman@movember.com)
- Participants are currently being recruited for the trial, which will go for approximately five and a half years. Initial findings are expected in 2017.

The Movember Foundation is a global men's health charity. The Foundation raises funds that deliver innovative, breakthrough programs that allow men to live happier, healthier and longer lives. Millions have joined the men's health movement, raising \$680 million and funding over 1,000 projects, focusing on prostate cancer, testicular cancer, poor mental health and physical inactivity.

For more information of the Movember Foundation's programs and funding and to sign up for this year's Movember, visit Movember.com.

CONTACT US

For more information and media enquiries contact Molly Hyndman
Mobile 0418 536 528. Telephone 03 8416 3900. Email molly.hyndman@movember.com